BSBritt A. Sterken

Britt A. Sterken

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Britt A. Sterken has a total of 23 co-authors. Here are the top co-authors by number of shared publications:

  • Cornelis F. Calkhoven

    European Research Institute for the Biology of Ageing (ERIBA), University Medical Center Groningen (UMCG) University of Groningen Groningen the Netherlands

    2 shared publications
  • Gertrud Kortman

    European Research Institute for the Biology of Ageing (ERIBA), University Medical Center Groningen, University of Groningen, Groningen, The Netherlands

    2 shared publications
  • Alain de Bruin

    Department of Biomolecular Health Sciences, Faculty of Veterinary Medicine, Utrecht University, Utrecht, the Netherlands

    1 shared publication
  • Alejandra Hernandez-Segura

    European Research Institute for the Biology of Ageing (ERIBA), University Medical Center Groningen, University of Groningen, Groningen, The Netherlands

    1 shared publication
  • Christine Müller

    European Research Institute for the Biology of Ageing (ERIBA), University Medical Center Groningen, University of Groningen, Groningen, The Netherlands

    1 shared publication
  • Christine Müller

    European Research Institute for the Biology of Ageing (ERIBA), University Medical Center Groningen (UMCG) University of Groningen Groningen the Netherlands

    1 shared publication

Latest Publications

  • Open Access

    C/EBPβ isoform-specific regulation of migration and invasion in triple-negative breast cancer cells

    by Britt A. Sterken, Tobias Ackermann, Christine Müller, Hidde R. Zuidhof, Gertrud Kortman, Alejandra Hernandez-Segura, Mathilde Broekhuis, Diana Spierings, Victor Guryev, Cornelis F. Calkhoven

    The transcription factor C/EBPβ is a master regulator of mammary gland development and tissue remodelling during lactation. TheCEBPB-mRNA is translated into three distinct protein isoforms named C/EBPβ-LAP1, -LAP2 and -LIP that are functionally different. The smaller isoform LIP lacks the N-terminal transactivation domains and is considered to act as an inhibitor of the transactivating LAP1/2 isoforms by competitive binding for the same DNA recognition sequences. Aberrantly high expression of LIP is associated with mammary epithelial proliferation and is found in grade III, estrogen receptor (ER) and progesterone (PR) receptor-negative human breast cancer. Here, we show that reverting the high LIP/LAP ratios in triple-negative breast cancer (TNBC) cell lines into low LIP/LAP ratios by overexpression of LAP reduces migration and matrix invasion of these TNBC cells. In addition, in untransformed MCF10A human mammary epithelial cells overexpression of LIP stimulates migration. Knockout ofCEBPBin TNBC cells where LIP expression prevails, resulted in strongly reduced migration that was accompanied by a downregulation of genes involved in cell migration, extracellular matrix production and cytoskeletal remodelling, many of which are epithelial to mesenchymal transition (EMT) marker genes. Together, this study suggests that the LIP/LAP ratio is involved in regulating breast cancer cell migration and invasion. This study together with studies from others shows that understanding the functions the C/EBPβ-isoforms in breast cancer development may reveal new avenues of treatment.


  • Open Access

    C/EBPβ-LIP induces cancer-type metabolic reprogramming by regulating the let-7/LIN28B circuit in mice

    by Tobias Ackermann, Götz Hartleben, Christine Müller, Guido Mastrobuoni, Marco Groth, Britt A. Sterken, Mohamad A. Zaini, Sameh A. Youssef, Hidde R. Zuidhof, Sara R. Krauss, et al.

    The transcription factors LAP1, LAP2 and LIP are derived from theCebpb-mRNA through the use of alternative start codons. High LIP expression has been associated with human cancer and increased cancer incidence in mice. However, how LIP contributes to cellular transformation is poorly understood. Here we present that LIP induces aerobic glycolysis and mitochondrial respiration reminiscent of cancer metabolism. We show that LIP-induced metabolic programming is dependent on the RNA-binding protein LIN28B, a translational regulator of glycolytic and mitochondrial enzymes with known oncogenic function. LIP activates LIN28B through repression of thelet-7microRNA family that targets theLin28b-mRNA. Transgenic mice overexpressing LIP have reduced levels oflet-7and increased LIN28B expression, which is associated with metabolic reprogramming as shown in primary bone marrow cells, and with hyperplasia in the skin. This study establishes LIP as an inducer of cancer-type metabolic reprogramming and as a regulator of thelet-7/LIN28B regulatory circuit.